BR9910642A - Análogos de benzimidazol como reguladores descendentes de ige - Google Patents

Análogos de benzimidazol como reguladores descendentes de ige

Info

Publication number
BR9910642A
BR9910642A BR9910642-6A BR9910642A BR9910642A BR 9910642 A BR9910642 A BR 9910642A BR 9910642 A BR9910642 A BR 9910642A BR 9910642 A BR9910642 A BR 9910642A
Authority
BR
Brazil
Prior art keywords
ige
regulators
descending
analogs
benzimidazole
Prior art date
Application number
BR9910642-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Jagadish Sircar
Mark L Richards
Michael G Campbell
Michael W Major
Original Assignee
Avanir Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22198947&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9910642(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Avanir Pharmaceuticals filed Critical Avanir Pharmaceuticals
Publication of BR9910642A publication Critical patent/BR9910642A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Amplifiers (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
BR9910642-6A 1998-05-22 1999-05-21 Análogos de benzimidazol como reguladores descendentes de ige BR9910642A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8649498P 1998-05-22 1998-05-22
PCT/US1999/011490 WO1999061020A1 (en) 1998-05-22 1999-05-21 BENZIMIDAZOLE ANALOGS AS DOWN-REGULATORS OF IgE

Publications (1)

Publication Number Publication Date
BR9910642A true BR9910642A (pt) 2001-10-09

Family

ID=22198947

Family Applications (3)

Application Number Title Priority Date Filing Date
BR9910642-6A BR9910642A (pt) 1998-05-22 1999-05-21 Análogos de benzimidazol como reguladores descendentes de ige
BR9910641-8A BR9910641A (pt) 1998-05-22 1999-05-21 Derivados de benzimidazol como moduladores de ige
BR9910640-0A BR9910640A (pt) 1998-05-22 1999-05-21 Compostos possuindo propriedades que afetam aige

Family Applications After (2)

Application Number Title Priority Date Filing Date
BR9910641-8A BR9910641A (pt) 1998-05-22 1999-05-21 Derivados de benzimidazol como moduladores de ige
BR9910640-0A BR9910640A (pt) 1998-05-22 1999-05-21 Compostos possuindo propriedades que afetam aige

Country Status (22)

Country Link
US (2) US6271390B1 (https=)
EP (3) EP1079830A1 (https=)
JP (3) JP2002516277A (https=)
KR (1) KR100591652B1 (https=)
CN (4) CN1311675A (https=)
AT (1) ATE292465T1 (https=)
AU (3) AU754562B2 (https=)
BR (3) BR9910642A (https=)
CA (3) CA2332985A1 (https=)
CZ (2) CZ20004351A3 (https=)
DE (1) DE69924607T2 (https=)
ES (1) ES2241285T3 (https=)
HU (3) HUP0102128A3 (https=)
IL (3) IL139828A0 (https=)
MX (3) MXPA00011422A (https=)
NO (3) NO20005889L (https=)
NZ (2) NZ508416A (https=)
PL (3) PL345560A1 (https=)
RU (2) RU2236221C2 (https=)
UA (2) UA67775C2 (https=)
WO (3) WO1999061020A1 (https=)
ZA (3) ZA200007754B (https=)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6919366B2 (en) 1998-05-22 2005-07-19 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
US6911462B2 (en) * 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
BR9910642A (pt) * 1998-05-22 2001-10-09 Avanir Pharmaceuticals Análogos de benzimidazol como reguladores descendentes de ige
BR9913562A (pt) 1998-09-11 2001-05-22 Ajinomoto Kk Derivados de benzeno, inibidor de ativação de ap-1 e nf-capa b, inibidor de produção de citoquina inflamatória, inibidor de produção de metaloprotease matricial ou inibidor de aparecimento de fator de adesão de célula inflamatório, e, agente antiinflamatório, anti-reumático, imunossupressor, inibidor de metástase cancerosa, remédio para arterioesclerose e agente antiviral
US6270746B1 (en) * 1999-02-17 2001-08-07 David H. Katz Assay for the identification of IgE antibody suppressors
TW502019B (en) * 1999-03-26 2002-09-11 Cocensys Inc Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof
BR0012046A (pt) 1999-07-01 2002-05-14 Ajinomoto Kk Composto heterocìclico, composição farmacêutica, inibidor de ativação de ap-1 ou um inibidor da ativação de nf-kappab, inibidor da produção de citocina inflamatória, e, inibidor da produção de metaloprotease de matriz ou inibidor da expressão do fator de adesão de célula inflamatória
WO2001016091A1 (en) 1999-09-01 2001-03-08 Ajinomoto Co.,Inc. Biscyclopropanecarboxylic acid amide compounds and medicinal use thereof
US6759425B2 (en) 1999-10-21 2004-07-06 Avanir Pharmaceuticals Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
US20070208087A1 (en) 2001-11-02 2007-09-06 Sanders Virginia J Compounds, compositions and methods for the treatment of inflammatory diseases
CZ20032691A3 (en) * 2001-03-12 2004-04-14 Avanir Pharmaceuticals Benzimidazole compounds for modulating ige and inhibiting cellular proliferation
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
BR0211513A (pt) * 2001-07-27 2005-08-30 Curis Inc Mediadores de caminhos sinalizantes de hedgehog, composições e usos relacionados ao mesmo
ATE369854T1 (de) 2001-10-19 2007-09-15 Ortho Mcneil Pharm Inc 2-phenyl benzimidazole und imidazo-[4,5]-pyridine als cds1/chk2-inhibitoren und adjuvantien in der chemotherapie oder strahlungstherapie zur behandlung von krebs
US20080081788A1 (en) * 2002-01-14 2008-04-03 Lipps Binie V Diagnosis and treatment for immunoglobulin E (IgE) implicated disorders
US20030157555A1 (en) * 2002-01-14 2003-08-21 Lipps Binie V. Diagnosis and treatment for immunoglobulin E ( IgE) implicated disorders
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
WO2003101927A1 (en) 2002-05-31 2003-12-11 Proteotech, Inc. Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's disease
EP1388535A1 (en) 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylated arylcycloalkylamines and their use as pharmaceuticals
DK1534335T4 (en) 2002-08-14 2015-10-05 Macrogenics Inc FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF
WO2004024655A2 (en) 2002-09-12 2004-03-25 Avanir Pharmaceuticals Phenyl-indole compounds for modulating ige and inhibiting cellular proliferation
TWI276631B (en) * 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
US20050239844A1 (en) * 2002-11-02 2005-10-27 Kyung-Lim Lee Composition fo preventing secretion of immunoglobulin e-dependent histamine releasing factor
GB2397301A (en) * 2003-01-14 2004-07-21 Novo Pharmaceuticals Ltd De Substituted 1,3,5-triazine derivatives
US7132440B2 (en) 2003-04-17 2006-11-07 Janssen Pharmaceutica, N.V. Substituted benzimidazoles and imidazo-[4,5]-pyridines
EP1651198A2 (en) * 2003-08-08 2006-05-03 Avanir Pharmaceuticals Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases
CN102911161A (zh) 2004-02-20 2013-02-06 贝林格尔.英格海姆国际有限公司 病毒聚合酶抑制剂
ATE453617T1 (de) * 2004-05-12 2010-01-15 Proteotech Inc Substituierte n-arylbenzamide und verwandte verbindungen zur behandlung von amyloidkrankheiten und synukleinopathien
ES2362102T3 (es) 2004-06-30 2011-06-28 Janssen Pharmaceutica Nv Eteres de bencimidazol e imidazopiridina sustituidos con arilo como agentes anticáncer.
WO2006040645A1 (en) * 2004-10-11 2006-04-20 Ranbaxy Laboratories Limited N-(3,5-dichloropyridin-4-yl)-2,4,5-alkoxy and 2,3,4-alkoxy benzamide derivatives as pde-iv (phophodiesterase type-iv) inhibitors for the treatment of inflammatory diseases such as asthma
JP5301999B2 (ja) † 2005-10-31 2013-09-25 メルク・シャープ・アンド・ドーム・コーポレーション Ｃｅｔｐ阻害薬
EP1790345A1 (en) * 2005-11-02 2007-05-30 Esbatech AG Triazin beta-secretase inhibitors
US7671221B2 (en) * 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
AU2006336504C9 (en) * 2005-12-28 2015-05-14 Vertex Pharmaceuticals Incorporated 1-(benzo [D] [1,3] dioxol-5-yl) -N- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-Binding Cassette transporters for the treatment of Cystic Fibrosis
ES2599319T3 (es) 2006-06-26 2017-02-01 Macrogenics, Inc. Anticuerpos específicos de Fc RIIB y métodos de uso de éstos
WO2010045633A2 (en) * 2008-10-17 2010-04-22 National Jewish Health Measurement and analysis of leukotrienes
US8546405B2 (en) 2008-12-23 2013-10-01 Abbott Laboratories Anti-viral compounds
SG172352A1 (en) 2008-12-23 2011-07-28 Abbott Lab Anti-viral compounds
US9278922B2 (en) 2009-04-15 2016-03-08 Abbvie Inc. Anti-viral compounds
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
EA020031B1 (ru) 2009-06-11 2014-08-29 Эббви Бахамаз Лтд. Противовирусные соединения
US8420655B2 (en) 2009-12-04 2013-04-16 Boehringer Ingelheim International Gmbh Benzimidazole inhibitors of leukotriene production
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
US9321735B2 (en) 2010-07-20 2016-04-26 Vestaron Corporation Insecticidal triazines and pyrimidines
JP5928958B2 (ja) 2010-10-29 2016-06-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン生成のベンゾイミダゾールインヒビター
WO2012061169A1 (en) 2010-11-01 2012-05-10 Boehringer Ingelheim International Gmbh Benzimidazole inhibitors of leukotriene production
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
US11548867B2 (en) 2017-07-19 2023-01-10 Idea Ya Biosciences, Inc. Amido compounds as AhR modulators
NZ773110A (en) * 2018-09-18 2024-11-29 Terns Inc Compounds for treating certain leukemias
CN110054558B (zh) * 2019-05-16 2022-03-25 海门瑞一医药科技有限公司 一种1-三氟甲基环丙烷-1-甲酸的制备方法
CN112441983B (zh) * 2019-08-29 2023-09-15 山东福长药业有限公司 一种基于苯并咪唑取代的硝基苯的化合物及其制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3017610A (en) * 1957-03-15 1962-01-16 Curtiss Wright Corp Electronic data file processor
US4939133A (en) 1985-10-01 1990-07-03 Warner-Lambert Company N-substituted-2-hydroxy-α-oxo-benzeneacetamides and pharmaceutical compositions having activity as modulators of the arachidonic acid cascade
LU86258A1 (fr) 1986-01-21 1987-09-03 Rech Dermatologiques C I R D S Composes benzamido aromatique,leur procede de preparation et leur utilisation en medecine humaine ou veterinaire et en cosmetique
US4744026A (en) * 1986-04-11 1988-05-10 American Telephone And Telegraph Company, At&T Bell Laboratories Methods and apparatus for efficient resource allocation
IT1232252B (it) 1989-02-22 1992-01-28 Rotta Research Lab Derivati della n fenil benzamide ad attivita' antiulcera ed antiallerica e procedimento per la loro preparazione
EP0428939B1 (de) * 1989-11-21 1996-01-17 Bayer Ag Cumarinderivate, Verfahren zu ihrer Herstellung, ihre Verwendung und Thiazolyl-essigsäurederivate als Zwischenprodukte
EP0469477B1 (en) * 1990-08-02 1995-09-20 F. Hoffmann-La Roche Ag Antiallergic combination
IE71647B1 (en) * 1991-01-28 1997-02-26 Rhone Poulenc Rorer Ltd Benzamide derivatives
FR2674856B1 (fr) * 1991-04-05 1993-07-30 Esteve Labor Dr Nouveaux antihistaminiques non sedatifs, derives de benzimidazole, leur procede de preparation et leur utilisation en tant que medicaments.
ES2102036T3 (es) 1992-06-15 1997-07-16 Celltech Therapeutics Ltd Derivados con grupo fenilo trisustituido utilizados como inhibidores selectivos de la fosfodiesterasa iv.
US5521813A (en) * 1993-01-15 1996-05-28 Strategic Weather Services System and method for the advanced prediction of weather impact on managerial planning applications
US5496826A (en) * 1994-09-02 1996-03-05 Bristol-Myers Squibb Company Pharmaceutical methods of using heterocyclic derivatives of N-phenylamides
JP3223090B2 (ja) * 1994-12-27 2001-10-29 三井化学株式会社 フェニルベンズイミダゾール誘導体
US5821258A (en) * 1994-12-27 1998-10-13 Mitsui Chemicals, Inc. Phenylbenzimidazole derivatives
RU2084451C1 (ru) * 1995-10-17 1997-07-20 Акционерное общество закрытого типа "Алмазный Центр" Способ получения 2-фенилбензимидазола
WO1998017267A1 (en) * 1996-10-23 1998-04-30 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
US6988076B2 (en) * 1997-05-21 2006-01-17 Khimetrics, Inc. Strategic planning and optimization system
BR9910642A (pt) * 1998-05-22 2001-10-09 Avanir Pharmaceuticals Análogos de benzimidazol como reguladores descendentes de ige
US6910017B1 (en) * 1999-03-05 2005-06-21 Profitlogic, Inc. Inventory and price decision support
US6405175B1 (en) * 1999-07-27 2002-06-11 David Way Ng Shopping scouts web site for rewarding customer referrals on product and price information with rewards scaled by the number of shoppers using the information
US6546387B1 (en) * 1999-11-15 2003-04-08 Transcom Software Inc. Computer network information management system and method using intelligent software agents
US20020042739A1 (en) * 2000-03-13 2002-04-11 Kannan Srinivasan Method and system for creating and administering internet marketing promotions
US20020023001A1 (en) * 2000-07-11 2002-02-21 Mcfarlin James A. Method and apparatus for online creation and sale of custom local store marketing materials
WO2002041219A1 (en) * 2000-11-15 2002-05-23 Manugistics Atlanta, Inc. Promotion pricing system and method
US20020198794A1 (en) * 2001-06-21 2002-12-26 Williams Edward P. Inventory management system for determining suggested part stocking levels for a vehicle dealer

Also Published As

Publication number Publication date
CA2332989A1 (en) 1999-12-02
HUP0101894A2 (hu) 2002-02-28
PL345219A1 (en) 2001-12-03
JP2002516274A (ja) 2002-06-04
RU2236220C2 (ru) 2004-09-20
ZA200007752B (en) 2001-12-05
NZ508413A (en) 2003-08-29
US6451829B2 (en) 2002-09-17
NO20005889L (no) 2001-01-22
HUP0101894A3 (en) 2002-07-29
HUP0102550A3 (en) 2002-11-28
EP1077700A1 (en) 2001-02-28
CA2332985A1 (en) 1999-12-02
KR20010030179A (ko) 2001-04-16
MXPA00011470A (es) 2002-10-17
NO20005887L (no) 2001-01-19
BR9910640A (pt) 2001-10-30
AU4197899A (en) 1999-12-13
HUP0102128A2 (hu) 2002-03-28
MXPA00011422A (es) 2002-12-13
AU4312099A (en) 1999-12-13
IL139828A0 (en) 2002-02-10
CN1721411A (zh) 2006-01-18
CZ20004350A3 (cs) 2002-02-13
NO20005888D0 (no) 2000-11-21
HUP0102128A3 (en) 2002-05-28
KR100591652B1 (ko) 2006-06-26
WO1999061020A1 (en) 1999-12-02
AU754562B2 (en) 2002-11-21
EP1079830A1 (en) 2001-03-07
ATE292465T1 (de) 2005-04-15
JP2002516276A (ja) 2002-06-04
PL345560A1 (en) 2001-12-17
CN1219510C (zh) 2005-09-21
CN1317965A (zh) 2001-10-17
DE69924607D1 (de) 2005-05-12
ZA200007753B (en) 2001-07-18
UA67775C2 (uk) 2004-07-15
PL345952A1 (en) 2002-01-14
ES2241285T3 (es) 2005-10-16
JP2002516277A (ja) 2002-06-04
BR9910641A (pt) 2001-10-02
CN1311679A (zh) 2001-09-05
IL139827A0 (en) 2002-02-10
ZA200007754B (en) 2001-08-16
EP1077700B1 (en) 2005-04-06
HUP0102550A2 (hu) 2001-10-28
NO20005887D0 (no) 2000-11-21
UA67774C2 (uk) 2004-07-15
DE69924607T2 (de) 2006-02-02
AU4094299A (en) 1999-12-13
WO1999061013A3 (en) 2000-04-06
AU754943B2 (en) 2002-11-28
MXPA00011467A (es) 2002-10-17
NO20005888L (no) 2001-01-22
CA2332999A1 (en) 1999-12-02
NO20005889D0 (no) 2000-11-21
NZ508416A (en) 2004-01-30
IL139826A0 (en) 2002-02-10
CZ20004351A3 (cs) 2001-10-17
CN1311675A (zh) 2001-09-05
US6271390B1 (en) 2001-08-07
EP1077695A2 (en) 2001-02-28
WO1999061019A1 (en) 1999-12-02
US20020010343A1 (en) 2002-01-24
RU2236221C2 (ru) 2004-09-20
WO1999061013A2 (en) 1999-12-02

Similar Documents

Publication Publication Date Title
BR9910642A (pt) Análogos de benzimidazol como reguladores descendentes de ige
YU45293A (sh) Morfolin i tiomorfolin tahikinin antagonisti receptora
BRPI0407305A (pt) Ligantes do receptor de canabinóides e seus usos
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
BR0012666A (pt) Imidazoimidazóis e triazóis como agentes anti-inflamatórios
TR200101772T2 (tr) IL-8 Reseptörü antagonistleri olarak hidroksi difenil üre sülfonamidler
ES2184794T3 (es) Profarmacos de morfolina como antagonistas de receptores de taquicininas.
UY26130A1 (es) Compuestos para tratar la obesidad
TR199900318T2 (xx) IL-8 resept�r antagonistleri.
GT199900101A (es) Inhibidores no peptidilicos de la union a las celulas dependientes de vla-4 utiles en el tratamiento de enfermedadesinflamatorias, autoinmunes y respiratorias.
EA200401341A1 (ru) Применение остеопротегерина для лечения и/или профилактики фиброзного заболевания
BR0213940A (pt) Análogos de lipoxina a4
BR0313769A (pt) Artigo descartável de vestir
BRPI0409097A (pt) derivados de imidazol para tratamento de distúrbios alérgicos e hiperproliferativos
ATE489361T1 (de) Derivate von alpha-phenylthiocarbon- und alpha- phenyloxycarbonsäuren, die für die behandlung von auf die aktivierung von ppar alpha ansprechende krankheiten geeignet sind
NO20050063L (no) 2-heteroaryl karboksamider
EP1126850A4 (en) TREATMENT OF RETINAL DISEASES
ATE271861T1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
DE69725457D1 (de) Piperazinderivate als neurokinin-antagonisten
BR9608245A (pt) Derivados de piperazino como antagonistas de neurocinina
MX9403032A (es) Quinolil-dihidropiridinas condensadas, procedimiento para su fabricacion ysu uso en medicamentos.
UY27372A1 (es) Derivados de bencimidazol 1-aril-2-n, s u o-sustituidos, su uso para la obtención de medicamentos y preparados farmacéuticos que contienen estos derivados
ATE406868T1 (de) Verwendung einer zusammensetzung mit vitamin k1- oxid oder einem derivat daraus zur behandlung und/oder vorbeugung von hautverletzungen bei säugern
BR9912153A (pt) Piperazinonas substituìdas e uso terapêuticos das mesmas
BR0113350A (pt) Aminoalquenilbenzoil-benzofuranos ou benzotiofenos, seu processo de preparação e as composições que os contêm

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE ACORDO COM OS ARTIGOS 8O, 11, 13, 24 E 25 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.